Massachusetts Financial Services
ALNY icon

Massachusetts Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Massachusetts Financial Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106M Sell
350,560
-145,444
-29% -$43.9M 0.03% 386
2026
Q1 		$164M Buy
496,004
+697
+0.1% +$237K 0.06% 281
2025
Q4 		$197M Buy
495,307
+138,778
+39% +$61.4M 0.06% 270
2025
Q3 		$163M Buy
+356,529
New +$145M 0.05% 315
2024
Q1 		– Sell
-112,240
Closed -$21.5M – 841
2023
Q4 		$21.5M Sell
112,240
-575,988
-84% -$98.1M 0.01% 563
2023
Q3 		$122M Buy
688,228
+15,831
+2% +$3.02M 0.04% 332
2023
Q2 		$128M Sell
672,397
-93,375
-12% -$18.5M 0.04% 327
2023
Q1 		$153M Buy
765,772
+10,230
+1% +$2.15M 0.05% 281
2022
Q4 		$180M Buy
755,542
+219,943
+41% +$46.9M 0.06% 252
2022
Q3 		$107M Buy
535,599
+191,310
+56% +$36.5M 0.04% 327
2022
Q2 		$50.2M Buy
344,289
+41,546
+14% +$5.89M 0.02% 453
2022
Q1 		$49.4M Sell
302,743
-1,019,468
-77% -$155M 0.01% 483
2021
Q4 		$224M Sell
1,322,211
-43,076
-3% -$8.01M 0.06% 259
2021
Q3 		$258M Sell
1,365,287
-9,856
-0.7% -$1.85M 0.08% 223
2021
Q2 		$233M Sell
1,375,143
-86,919
-6% -$12.7M 0.07% 240
2021
Q1 		$206M Sell
1,462,062
-301,305
-17% -$45.3M 0.06% 254
2020
Q4 		$229M Sell
1,763,367
-142,023
-7% -$19M 0.07% 227
2020
Q3 		$277M Buy
1,905,390
+842,211
+79% +$120M 0.1% 192
2020
Q2 		$157M Buy
+1,063,179
New +$143M 0.06% 244
2016
Q4 		– Sell
-78,048
Closed -$5.29M – 855
2016
Q3 		$5.29M Buy
78,048
+767
+1% +$54.1K ﹤0.01% 641
2016
Q2 		$4.29M Sell
77,281
-2,697
-3% -$170K ﹤0.01% 656
2016
Q1 		$5.02M Buy
79,978
+985
+1% +$65.5K ﹤0.01% 641
2015
Q4 		$7.44M Sell
78,993
-537
-0.7% -$49.8K ﹤0.01% 613
2015
Q3 		$6.39M Sell
79,530
-1,472
-2% -$164K ﹤0.01% 643
2015
Q2 		$9.71M Sell
81,002
-1,268
-2% -$152K ﹤0.01% 617
2015
Q1 		$8.59M Buy
82,270
+2,548
+3% +$258K ﹤0.01% 628
2014
Q4 		$7.73M Buy
+79,722
New +$7.39M ﹤0.01% 638

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Massachusetts Financial Services's ALNY Position: Q2 2026 in Review

Massachusetts Financial Services reduced its Alnylam Pharmaceuticals (ALNY) stake by 29% in Q2 2026, selling an estimated $43.9M and leaving 350,560 shares worth $106M. The position accounts for 0.03% of the portfolio, ranked #386.

Massachusetts Financial Services first reported a position in ALNY in Q4 2014 and has held it in 27 quarters since. The position peaked at $277M in Q3 2020. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Massachusetts Financial Services held 350,560 shares of Alnylam Pharmaceuticals worth $106M as of Q2 2026.
  • Massachusetts Financial Services sold 145,444 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $43.9M.
  • Alnylam Pharmaceuticals made up 0.03% of Massachusetts Financial Services's portfolio in Q2 2026, its #386 holding.
  • Massachusetts Financial Services first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 27 quarters since.
  • Massachusetts Financial Services's Alnylam Pharmaceuticals position peaked at $277M in Q3 2020.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.